Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 13/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | VEGFA | P15692 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2155319 | 0.81 | PDE4A (0.56) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL16878944 | 0.80 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL12498580 | 0.74 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL12498577 | 0.74 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL559921 | 0.74 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL560015 | 0.74 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL4187604 | 0.74 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL4187595 | 0.74 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL560408 | 0.74 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL22551141 | 0.72 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3089974-B1 | NOVEL IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | IPSEN PHARMA SAS (FR) | 2019-02-20 | — | — | EP | disclosed |
| CN-105849101-B | New imidazolidine -2,4- derovatives | 益普生制药股份有限公司 | 2019-02-19 | — | — | CN | disclosed |
| US-9975880-B2 | Imidazolidine-2,4-dione dervatives | IPSEN PHARMA S.A.S. (FR) | 2018-05-22 | — | — | US | disclosed |
| EP-3089974-A1 | NOVEL IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | IPSEN PHARMA S.A.S. (FR) | 2016-11-09 | — | — | EP | disclosed |
| US-20160318908-A1 | NOVEL IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | IPSEN PHARMA S.A.S. (FR) | 2016-11-03 | — | — | US | disclosed |
| CN-105849101-A | Novel imidazolidine-2,4-dione derivatives | 益普生制药股份有限公司 | 2016-08-10 | — | — | CN | disclosed |
| WO-2015100617-A1 | NOVEL IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | BEAUFOUR-IPSEN (TIANJIN) PHARMACEUTICAL CO., LTD. (CN) | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318908-A1 | NOVEL IMIDAZOLIDINE-2,4-DIONE DERIVATIVES | MKI67, CCNI, CDKN1A | PDE4A 1489/4885PDE4B 1408/4885PDE4C 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.